Compare TYRA & CCSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | CCSI |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 549.8M |
| IPO Year | 2021 | N/A |
| Metric | TYRA | CCSI |
|---|---|---|
| Price | $22.54 | $23.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $31.20 | $29.00 |
| AVG Volume (30 Days) | ★ 570.8K | 177.7K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.22 |
| Revenue | N/A | ★ $349,609,000.00 |
| Revenue This Year | N/A | $1.67 |
| Revenue Next Year | N/A | $0.97 |
| P/E Ratio | ★ N/A | $5.63 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.42 | $17.84 |
| 52 Week High | $24.05 | $32.10 |
| Indicator | TYRA | CCSI |
|---|---|---|
| Relative Strength Index (RSI) | 69.31 | 53.53 |
| Support Level | $21.66 | $21.92 |
| Resistance Level | $24.05 | $23.14 |
| Average True Range (ATR) | 1.31 | 0.77 |
| MACD | -0.05 | 0.40 |
| Stochastic Oscillator | 67.04 | 99.36 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.